# NasoVAX in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19)

> **NCT04442230** · PHASE2 · TERMINATED · sponsor: **Altimmune, Inc.** · enrollment: 48 (actual)

## Conditions studied

- Coronavirus Infection

## Interventions

- **BIOLOGICAL:** NasoVAX
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04442230
- **Lead sponsor:** Altimmune, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-10-10
- **Primary completion:** 2021-02-15
- **Final completion:** 2021-02-15
- **Target enrollment:** 48 (ACTUAL)
- **Why stopped:** Enrollment
- **Last updated:** 2022-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04442230

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04442230, "NasoVAX in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19)". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT04442230. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*